

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-35 (cancelled).

36. (new) Method for the treatment of a disease or of a lesion involving cellular apoptosis, reduction of the survival of cells and/or destruction of cells, comprising administering an affective amount of macrophages.

37. (new) Method according to claim 36, further comprising improving survival of a first type of cells, for the treatment of a disease or of a lesion involving the destruction of a second type of cells or of a tissue containing said second type of cells, said first type of cells being selected from the group consisting of precursor cells and stem cells, said second type of cells being selected from the group consisting of precursor cells, stem cells and any type of differentiated cells.

38. (new) The method according to claim 37, wherein said first type of cells is to be grafted into a mammal for the treatment of one or several focal lesions.

39. (new) The method according to claim 37, wherein said first type of cells and / or macrophages are autologous for said mammal.

40. (new) The method according to claim 36, wherein a bone or of muscular lesion is treated.

41. (new) The method according to claim 40, wherein said muscular lesion is a cardiac lesion, said cardiac lesion being a myocardial infarction, coronary thrombosis, dilated cardiomyopathy or cardiomyocyte dysfunction subsequent to, or resulting from, a genetic defect.

42. (new) The method according to claim 36, wherein macrophages act as a inhibitors of apoptosis of said first type of cells by cell to cell contact between the surface of respectively said macrophages and said first type of cells.

43. (new) The method according to claim 36, wherein macrophages act as a stromal support for said first type of cells.

44. (new) The method according to claim 37, wherein said first type of cells is selected from the group consisting of: myogenic precursor cells, endothelial precursor cells, hematopoietic precursor cells, bone marrow precursor cells, mesenchymal precursor cells, neuronal precursor cells and multipotent adult stem cells.

45. (new) A method for preparing a composition comprising adding macrophages and at least one first type of cells, in association with a pharmaceutically acceptable vehicle, for the preparation of said composition to be grafted into a mammal, said first type of cells being selected from the group consisting of precursor cells and stem cells.

46. (new) The method according to claim 45, wherein said first type of cells are autologous to said mammal.

47. (new) A method for the treatment of a disease or of a lesion involving the destruction of cells, comprising adding an affective amount of a composition according to claim 53.

48. (new) A method for the treatment of one or several focal lesions, comprising adding an affective amount of a composition according to claim 53.

49. (new) A method for the treatment of bone or muscular lesion, comprising adding an affective amount of a composition according to claim 53.

50. (new) A method for the treatment of cardiac lesion, said cardiac lesion being a myocardial infarction, coronary thrombosis, dilated cardiomyopathy or cardiomyocyte dysfunction resulting from a genetic defect, comprising adding an affective amount of a composition according to claim 53.

51. (new) The method according to claim 50 wherein said first type of cells are myogenic precursor cells.

52. (new) The method according to claim 45 wherein said composition contains from about  $0.5 \cdot 10^8$  to about  $7.5 \cdot 10^8$  macrophages and from about  $0.5 \cdot 10^8$  to about  $7.5 \cdot 10^8$  of said first type of cells.

53. (new) A pharmaceutical composition containing at least one first type of cells, said first type of cells being precursor cells or stem cells, and macrophages, in association with a pharmaceutically acceptable vehicle.

54. (new) The pharmaceutical composition according to claim 53, wherein said first type of cells is chosen among a group consisting of: myogenic precursor cells, endothelial precursor

cells, hematopoietic precursor cells, bone marrow precursor cells, mesenchymal precursor cells, neuronal precursor cells and multipotent adult stem cells.

55. (new) The pharmaceutical composition according to claim 53 wherein the ratio between said first type of cells and macrophages, as expressed in number of cells, is comprised between about 1/10 and about 10/1.

56. (new) The pharmaceutical composition according to claim 53, wherein the percentage of macrophages, expressed in relation to the total number of cells in the composition, is from about 5 % to about 70 %.

57. (new) The pharmaceutical composition according to claim 53, further comprising frozen precursors cells or stem cells on one hand and frozen macrophages on other hand, in pharmaceutically acceptable cryopreservant and vehicle.

58. (new) The pharmaceutical composition claim 53, comprising macrophages and myogenic precursor cells.

59. (new) The pharmaceutical composition according to claim 58, wherein the ratio between macrophages and myogenic precursor cells, as expressed in number of cells, is comprised between about 1/10 and about 10/1.

60. (new) The pharmaceutical composition according to claim 59, wherein the percentage of cells, expressed in relation of the total number of cells in the composition, is comprised from about 10 % to about 80 % of macrophages, and from about 10 % to about 80 % of myogenic cell precursor cells.

61. (new) The pharmaceutical composition according to claim 57 containing from about  $0.5 \times 10^8$  to about  $7.5 \times 10^8$ .

62. (new) The pharmaceutical composition according to claim 57, comprising from about  $0.5 \times 10^8$  to about  $7.5 \times 10^8$  myogenic precursor cells.

63. (new) A binary complex made of a myogenic precursor cell and a macrophage, interacting by cell to cell contacts between surface receptors on the surface of, respectively, macrophage and myogenic precursor cell.

64. (new) A binary complex according to claim 62 wherein cell to cell contacts are mediated, at least partly, via cell surface molecules VLA4 and VCAM1, on the surface of myogenic precursor cell and macrophage.

65. (new) A binary complex according to claim 62 wherein cell to cell contacts are mediated, at least partly, via cell surface molecules fractalkine (CX3CL1) and CX3CR1, on the surface of myogenic precursor cell and macrophage.

66. (new) A process for preparing pharmaceutical compositions containing a first type of cells and macrophages, comprising contacting a first type of cells, selected from the group consisting of precursor cells and stem cells, and macrophages.

67. (new) The process according to claim 65 wherein said first type of cells and said macrophages are contacted for a time sufficient to allow at least one cycle of cellular division of said first type of cells

68. (new) A product containing macrophages and a first type of cells, being possibly precursor cells or stem cells, as a combined preparation for the separate, simultaneous or sequential use in cellular graft into a mammal.

69. (new) The product according to claim 67, wherein precursor cells are myogenic precursor cells.

70. (new) The product according to claim 67, where aliquots of the first type of cells and the macrophages are kept frozen in acceptable vehicle until thawing for the injection.